Ascletis hits 4-week high on initiating US Phase I study on obesity drug
09/09/2026 03:03
BUZZ-Ascletis hits 4-week high on initiating US Phase I study on obesity drug ** Shares of Ascletis Pharma Inc 1672.HK climb 5.6% to HK$10.75, their highest since August 13
** Stock on track for biggest one-day pct gain since August 7
** Pharmaceutical products producer says it has initiated a U.S. Phase I study of ASC36 oral tablets for treatment of obesity after receiving Investigational New Drug clearance from the U.S. Food and Drug Administration
** ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for seven days in non-human primates - co
** YTD, stock down 7.3%, while Hang Seng Biotech Index .HSBIO up 10.7%
(Reporting by Donny Kwok)
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management